Focus without stimulants stack — sustained attention, no caffeine
For people who cannot tolerate stimulants — pregnancy, lactation, anxiety disorders, atrial fibrillation, hypertension that's not yet on target — or who simply don't want the rebound and sleep debt that comes with leaning on caffeine. The stack below targets the cognitive and attentional pathways without raising heart rate, blood pressure, or sympathetic tone. Effects are quieter than caffeine; consistency over weeks matters more than acute kick.
The stack is layered: a Foundation that almost everyone benefits from, a Performance layer for active task focus, and Optional supplements where the evidence applies to specific subsets (mood-driven attention, age-related decline, acute-stress cognition).
TL;DR — the stack
| Supplement | Layer | Dose & timing | Tier |
|---|---|---|---|
| Creatine monohydrate | Foundation | 3–5 g/day, any time | Tier 1 |
| L-Theanine (standalone) | Foundation | 100–200 mg, 30 min before focus block | Tier 2 |
| Citicoline (CDP-Choline) | Performance | 250–500 mg, morning | Tier 2 |
| Magnesium L-threonate | Performance | 1.5–2 g (≈144 mg elemental), evening | Tier 2 |
| Bacopa monnieri | Performance | 300 mg standardised extract with food | Tier 3 |
| Tyrosine (L-tyrosine) | Optional | 1–2 g, 60 min before high-stress task | Tier 2 |
| Saffron (Crocus sativus) | Optional | 28–30 mg standardised extract, daily | Tier 1 |
Per-supplement detail
Dose & timing. 3–5 g/day with water, any time of day. Optional loading (20 g/day for 5–7 days) accelerates saturation.
Why. Creatine raises brain phosphocreatine, buffering ATP demand under cognitive load and especially under sleep restriction. The Xu et al. 2024 systematic review of 16 RCTs (492 participants, PMID 39070254) found significant improvements in memory (SMD 0.31), attention/processing speed (SMD −0.51 reaction time), with stronger effects in adults 18–60 and in disease states. Sleep-deprivation trials show even larger acute effects.
Funder mix. Mostly public/academic; supplement-industry trials are present but the meta-analytic signal is consistent across funder types.
Notes. Cheapest, most evidence-rich nootropic in the stack. Stay hydrated. Monohydrate is the studied form — pricier "HCl" and "buffered" forms have no clinical advantage.
Dose & timing. 100–200 mg, 30 minutes before a focus block. (For the caffeine-paired version see the L-theanine + caffeine stack — outside this stack's no-stimulant scope.)
Why. Theanine raises alpha-wave activity (the EEG signature of relaxed alertness) and partially modulates the NMDA receptor. The Hidese et al. 2019 RCT (PMID 31623400) found sustained-attention and cognitive-flexibility improvements over four weeks at 200 mg/day. Effect is "calm focus" rather than acute boost — useful when anxiety is competing with attention.
Funder mix. Industry (Taiyo) plus independent.
Notes. Among the safest supplements known. No tolerance noted in 8-week trials.
Dose & timing. 250–500 mg in the morning. Mildly stimulating — avoid evening doses.
Why. Citicoline crosses the blood-brain barrier and supplies both choline (acetylcholine substrate) and cytidine (phospholipid synthesis). Knott et al. 2015 (PMID 26221764) found 250 mg and 500 mg over 28 days improved attention and psychomotor speed in healthy adolescent females; multiple older-adult and post-stroke trials report improvements in attention and processing speed. Better tolerated than alpha-GPC and without alpha-GPC's disputed Korean stroke-association signal.
Funder mix. Mix of academic (post-stroke literature) and supplement-industry (cognition trials in healthy adults).
Notes. Pair with the choline-dependent acetylcholine-receptor system; particularly noticeable benefit if dietary choline intake is low (which describes ~90% of adults).
Dose & timing. 1.5–2 g of the L-threonate compound (≈144 mg elemental magnesium) in the evening.
Why. L-threonate is the only magnesium form clearly shown to raise CNS magnesium in animals; Liu et al. 2016 (PMID 26519439) found 12 weeks of magnesium L-threonate (Magtein) at 1.5–2 g/day improved measures of executive function, working memory, attention, and episodic memory in older adults with cognitive complaints. Effect sizes are modest but consistent across the limited human dataset.
Funder mix. Industry-funded (Magceutics/AIDP) plus a small number of academic-led replications.
Notes. Take in the evening — it pairs with the sleep benefit of magnesium and avoids stacking minerals with morning thyroid medication.
Dose & timing. 300 mg of standardised extract (40–55% bacosides) with food. Allow 12 weeks for full effect.
Why. Bacopa's bacosides modulate cholinergic and serotonergic transmission and have neuroprotective signalling effects. Kongkeaw et al. 2014 meta-analysis (PMID 24252493) of nine RCTs found significant improvement in delayed-recall memory and information-processing speed; benefit only emerges after roughly 12 weeks of daily use.
Funder mix. Mostly academic and Indian government/CSIR-funded trials, with some supplement-industry studies.
Notes. Always take with food — empty-stomach use causes nausea. Some report mild evening alertness; switch to morning dose if it interferes with sleep.
Dose & timing. 1–2 g taken 60 minutes before a high-stress cognitive task. Situational, not daily.
Why. Tyrosine is the precursor to dopamine and norepinephrine; under acute stress (sleep deprivation, cold, multitasking) those catecholamines deplete and tyrosine supplementation preserves cognitive performance. Jongkees et al. 2015 (PMID 26424423) reviewed 15 trials and concluded tyrosine reliably restores working memory and information processing under acute stress conditions but does not improve cognition in unstressed states.
Funder mix. Predominantly public/academic and military research.
Notes. Skip if you have hyperthyroidism or take MAOIs — additive catecholaminergic effect. Caution with SSRIs and stimulant medications.
Dose & timing. 28–30 mg standardised extract daily. Allow 4–8 weeks before assessing.
Why. Saffron's mood and cognition signal is strong specifically when low-grade depression or anhedonia is competing with attention. The Cheng et al. 2025 nutraceutical network meta-analysis (192 trials, 17,437 patients, PMID 40314175) identified saffron as one of only four nutraceutical monotherapies with effect size superior to standard antidepressants for mild-moderate depression (SMD 0.69). The cognitive lift follows the mood lift.
Funder mix. Mix of academic and supplement-industry trials; the network meta-analysis is independent.
Notes. Do not combine with SSRIs, SNRIs, or MAOIs without prescriber guidance — additive serotonergic risk.
Daily timing — when to take what
MiddayL-Theanine 100–200 mg, 30 min before main focus block. Tyrosine 1–2 g, 60 min before stress-heavy task (situational only).
AnytimeCreatine 3–5 g — timing does not matter, daily consistency does.
EveningMagnesium L-threonate 1.5–2 g with dinner.
Pre-bedLights off, screens away. (No caffeine after 14:00 if you do drink any.)
Within-stack synergies
L-theanine + caffeine is the most-validated cognitive synergy in the literature (pairing entry p5, strength 5). This stack deliberately omits the caffeine half — but the theanine alone still works through the alpha-wave route. If you choose to add coffee separately, the same 200 mg theanine : 100 mg caffeine ratio applies and side-effect-offset entry p115 (strength 4) covers the jitter-reduction benefit.
Magnesium + creatine work on different ATP pathways (calcium handling vs. phosphocreatine buffering) and stack cleanly. Citicoline supplies the choline for the acetylcholine system that bacopa modulates downstream — mechanistically complementary. No within-stack antagonisms identified in our pairings database.
Interactions to watch
- SSRIs / SNRIs. Saffron and tyrosine both carry serotonergic / catecholaminergic interaction caution per our SSRI interaction page. Discuss with your prescriber before adding either.
- MAOIs. Tyrosine is on the avoid list for MAOIs (hypertensive-crisis risk). Saffron is on caution. Skip both if you take an MAOI.
- Stimulant medications (Adderall, Vyvanse, Ritalin). Tyrosine is additive — do not stack without specialist input.
- Levothyroxine. Magnesium L-threonate (taken at dinner) avoids the morning thyroid window — keep separation ≥4 hours.
- Anticoagulants. No major within-stack concerns. Ginkgo (which we explicitly recommend against, below) is the cognitive supplement to watch for warfarin interaction.
- Hyperthyroidism, uncontrolled hypertension. Skip tyrosine.
Don't bother — what to skip
Cognitive supplements have a particularly high marketing-to-evidence ratio. These are the worst offenders.
- Ginkgo biloba for prevention. The GEM trial (DeKosky et al. 2008, PMID 19017911) randomised 3,069 older adults to 240 mg/day Ginkgo or placebo for a mean 6.1 years and found no reduction in all-cause dementia or Alzheimer's incidence. The Cochrane review (Birks & Grimley Evans, PMID 19160216) reached the same conclusion. Add antiplatelet activity that interacts with warfarin and aspirin, and the cost-benefit turns negative.
- Lion's mane mushroom for healthy adults. Animal nerve-growth-factor data is genuinely interesting; human trials in cognitively healthy adults are tiny and inconsistent. Li et al. 2020 (PMID 32443735) reviewed the small dataset and concluded evidence is "preliminary" — too thin to recommend for general focus.
- Phenylpiracetam, noopept and other unregulated "racetams". Not cleared by FDA as supplements; pharmacological activity sits in a regulatory grey zone with no quality control or long-term safety data. Several have been on FDA warning lists.
- Generic "nootropic blends" with proprietary doses. If the label hides individual ingredient amounts behind a "proprietary blend", you cannot tell whether any single component is at a clinical dose. Industry-wide, most blends are massively under-dosed on the ingredients that work.
Sources
- Xu C, Bi S, Zhang W, et al. The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis. Front Nutr. 2024;11:1424972. PMID: 39070254.
- Hidese S, Ogawa S, Ota M, et al. Effects of L-theanine administration on stress-related symptoms and cognitive functions in healthy adults: a randomized controlled trial. Nutrients. 2019;11(10):2362. PMID: 31623400.
- Knott V, de la Salle S, Choueiry J, et al. Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers. Pharmacol Biochem Behav. 2015;131:119–129. PMID: 26221764.
- Liu G, Weinger JG, Lu ZL, et al. Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial. J Alzheimers Dis. 2016;49(4):971–990. PMID: 26519439.
- Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528–535. PMID: 24252493.
- Jongkees BJ, Hommel B, Kühn S, et al. Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands — a review. J Psychiatr Res. 2015;70:50–57. PMID: 26424423.
- Cheng YC, Huang YC, Huang WL, et al. Comparative efficacy and acceptability of nutraceuticals for major depressive disorder: a network meta-analysis. Nutrients. 2025. PMID: 40314175.
- DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial (GEM Study). JAMA. 2008;300(19):2253–2262. PMID: 19017911.
- Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;(1):CD003120. PMID: 19160216.
- Li IC, Lee LY, Tzeng TT, et al. Neurohealth properties of Hericium erinaceus mycelia enriched with erinacines. Behav Neurol. 2020;2020:2418196. PMID: 32443735.
- Roodenrys S, Booth D, Bulzomi S, et al. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279–281. PMID: 12093601.
- Lyon MR, Kapoor MP, Juneja LR. The effects of L-theanine (Suntheanine) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD). Altern Med Rev. 2011;16(4):348–354. PMID: 22214254.